We have previously shown that decitabine, following intracellular modification, binds to TYMS using a high throughput CETSA-based screen with the K562 chronic myeloid leukemia cell line [26]. This evidence concerns the gene TYMS and chronic myelogenous leukemia, BCR-ABL1 positive.